Open-Angle Glaucoma - Pipeline Insight, 2024

This “Open-Angle Glaucoma - Pipeline Insight, 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Open-Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Open-Angle Glaucoma: Understanding

Open-Angle Glaucoma: Overview

Open-angle glaucoma (OAG) is the most prevalent form of glaucoma, characterized by a gradual increase in intraocular pressure (IOP) that leads to optic nerve damage. Unlike other forms of glaucoma, the drainage angle in OAG remains open, but the trabecular meshwork through which fluid drains becomes partially blocked. This blockage causes a buildup of pressure inside the eye, which over time, damages the optic nerve fibers, resulting in vision loss. The disease is often asymptomatic in its early stages, which is why it is referred to as "the silent thief of sight."

Risk factors for OAG include age, with individuals over 40 being more susceptible, and ethnicity, as African Americans, Hispanics, and Asians have higher prevalence rates. A family history of glaucoma significantly increases one's risk, and other medical conditions such as diabetes, hypertension, and myopia are also contributing factors. Certain medications like corticosteroids, previous eye injuries, and having thin corneas can further elevate the risk of developing OAG.

Diagnosis involves a comprehensive eye examination that includes measuring IOP, assessing corneal thickness, and examining the drainage angle. Imaging techniques like optical coherence tomography (OCT) and visual field tests are used to detect and monitor optic nerve damage. Treatment primarily focuses on lowering IOP through medications, laser therapy, or surgery, depending on the severity of the condition. Eye drops and oral medications are often the first line of defense, while more advanced cases may require laser procedures or surgical interventions to enhance fluid drainage from the eye.

Regular monitoring and treatment adjustments are essential for managing OAG and preventing vision loss. Patients are encouraged to maintain a healthy lifestyle, undergo regular eye examinations, and adhere to their prescribed treatment regimens. Although vision loss from OAG is irreversible, early detection and consistent management can significantly slow the progression of the disease and help maintain vision quality.

"Open-Angle Glaucoma- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Open-Angle Glaucoma pipeline landscape is provided which includes the disease overview and Open-Angle Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Open-Angle Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Open-Angle Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Open-Angle Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve Open-Angle Glaucoma.

Open-Angle Glaucoma Emerging Drugs Chapters

This segment of the Open-Angle Glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Open-Angle Glaucoma Emerging Drugs

NCX 470: Nicox Ophthalmics

NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog that is currently being developed by Nicox Ophthalmics. NCX-470 may assist glaucoma patients by a mechanism other than IOP lowering, notably by enhancing ocular perfusion. IOP reduction is the most common treatment for glaucoma, and preliminary studies suggest that if approved, NCX-470's dual mechanistic approach (nitric oxide donation and prostaglandin F2 activity) could make it the most effective single-agent glaucoma medicine in terms of IOP-lowering efficacy. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.

BTQ-1902: Betaliq, Inc.

BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta blocker. Beta blockers are one of the most commonly prescribed classes of medicines to treat glaucoma. Beta blockers reduce Intraocular Pressure (IOP) by blockade of sympathetic nerve endings in the ciliary epithelium causing a fall in aqueous humour production. Beta blockers are often prescribed in combination with other glaucoma medications. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Open-Angle Glaucoma.

TO-O-1001: Theratocular Biotek

TO-O-1001 (MG-O-1001) eye drops is a patented new generation Rho kinase (ROCK) inhibitor for treating patients with primary open-angle glaucoma or ocular hypertension. Its therapeutic potency is established through a dual-targeting mechanism, which in turn leads to relaxation of the cells of trabecular meshwork and the inner walls of Schlemm’s canal. The combined results are an increase of aqueous humor outflow, which is necessary to achieve the intraocular pressure lowering effect. Animal studies showed superior efficacy results in IOP-lowering. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of open-angle glaucoma or ocular hypertension.

Open-Angle Glaucoma: Therapeutic Assessment

This segment of the report provides insights about the different Open-Angle Glaucoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Open-Angle Glaucoma

There are approx. 18+ key companies which are developing the therapies for Open-Angle Glaucoma. The companies which have their Open-Angle Glaucoma drug candidates in the most advanced stage, i.e. Phase III include, Nicox Ophthalmics.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Open-Angle Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Open-Angle Glaucoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Open-Angle Glaucoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Open-Angle Glaucoma drugs.

Open-Angle Glaucoma Report Insights

• Open-Angle Glaucoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Open-Angle Glaucoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Open-Angle Glaucoma drugs?
• How many Open-Angle Glaucoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Open-Angle Glaucoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Open-Angle Glaucoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Open-Angle Glaucoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Nicox Ophthalmics
• Betaliq, Inc.
• Qlaris Bio
• Aerpio Pharmaceuticals
• Theratocular Biotek
• PolyActiva Pty Ltd.
• Whitecap Biosciences
• JeniVision
• EMS

Key Products

• NCX 470
• BTQ-1902
• QLS-101
• Razuprotafib
• TO-O-1001
• PA5108
• WB-007
• JV-GL1
• Bremen

This product will be delivered within 1-3 business days.